Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129885 | 0.88 | TP53 (0.57) | RAB9AKDM4EPOLBGAAHTT | |
| SCHEMBL17051575 | 0.82 | NPC1 (0.44) | RAB9AKDM4EPOLBSMN1; SMN2NPC1 | |
| SCHEMBL1867087 | 0.79 | TP53 (0.54) | RAB9AKDM4EPOLBGAAHTT | |
| SCHEMBL187006 | 0.78 | NAPRT (0.48) | RAB9AKDM4EPOLBGAAHTT | |
| SCHEMBL28680918 | 0.78 | RAB9A (0.45) | RAB9AKDM4EPOLBGAAHTT | |
| SCHEMBL18653550 | 0.76 | LDHA (0.51) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL23084949 | 0.76 | MAPT (0.45) | RAB9APOLBSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL10000239 | 0.76 | NPC1 (0.53) | RAB9AKDM4EPOLBSMN1; SMN2NPC1 | |
| SCHEMBL423171 | 0.76 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1ALDH1A1TP53 | |
| SCHEMBL26038867 | 0.75 | KMT2A (0.50) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892888-B1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-04-18 | — | — | EP | disclosed |
| US-9469631-B2 | N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-20150225390-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2892888-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037327-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | WO | disclosed |
| CN-1260781-A | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | SMITHKLINE BEECHAM PLC (GB) | 2000-07-19 | — | — | CN | disclosed |
| EP-0975593-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225390-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES THEREOF | GPR18, GPR39, GPR4 | RAB9A 830/4885KDM4E 3363/4885POLB 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.